PharmaShots | Incisive News in 3 Shots

Subscribe Now

Sensorion

Sensorion Reports Results from the P-IIa Trial of SENS-401 for Residual Hearing Preservation after Cochlear Implantation

Sensorion Reports Results from the P-IIa Trial of SENS-401 for Residual Hearing Preservation after Cochlear Implantation

March 11, 2024

Sensorion Concludes Patient Enrolment in the P-IIa Study of SENS-401 for Residual Hearing Preservation After Cochlear Implantation

Sensorion Concludes Patient Enrolment in the P-IIa Study of SENS-401 for Residual Hearing Preservation After Cochlear Implantation

February 1, 2024

Sensorion Receives Approval to Commence P-I/II Study of SENS-501 (OTOF-GT) for Hearing Impairment Across European Countries

Sensorion Receives Approval to Commence P-I/II Study of SENS-501 (OTOF-GT) for Hearing Impairment Across European Countries

January 19, 2024

Sensorion’s SENS-401 Receives Australia’s Approval for the Initiation of Proof-of-Concept Trial to Treat Hearing Impairment

Sensorion’s SENS-401 Receives Australia’s Approval for the Initiation of Proof-of-Concept Trial to Treat Hearing Impairment

July 1, 2022

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us